Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-21

Clinical Trial Update: A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme [Phase 4]

View source ↗

Summary

Phase 4 prospective study evaluating the safety and tolerability of a shorter infusion of Fabrazyme for Fabry disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Sanofi | Conditions: Fabry's Disease | Phase 4 | Status: COMPLETED | Results posted: 2025-10-21